Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Un doppio studio randomizzato di 6 e 18 mesi che valuta la sicurezza e l'efficacia di Buntanetap nei partecipanti con AD precoce (DUET-AD)

16 novembre 2026 aggiornato da: Annovis Bio Inc.

Un doppio studio clinico prospettico, randomizzato, controllato con placebo, in doppio cieco, della durata di 6 e 18 mesi, che valuta l'efficacia e la sicurezza di Buntanetap nel trattamento dei partecipanti con malattia di Alzheimer in fase iniziale

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

  • Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
  • Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
  • What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

  • Take buntanetap/Posiphen or a placebo every day for 18 months
  • Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
  • Complete pre- and post-clinic visit phone calls

Panoramica dello studio

Stato

Attivo, non reclutante

Tipo di studio

Interventistico

Iscrizione (Effettivo)

861

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Chandler, Arizona, Stati Uniti, 85286
        • MD First Research
      • Phoenix, Arizona, Stati Uniti, 85004
        • Xenoscience
      • Scottsdale, Arizona, Stati Uniti, 85258
        • Clinical Endpoints
    • California
      • Anaheim, California, Stati Uniti, 92805
        • Advanced Research Center
      • Canoga Park, California, Stati Uniti, 91303
        • Hope Clinical Research
      • Imperial, California, Stati Uniti, 92251
        • Sun Valley Research
      • Los Angeles, California, Stati Uniti, 90095
        • Mary S. Easton Center for Alzheimer's Research and Care, UCLA
      • Sacramento, California, Stati Uniti, 95816
        • UC Davis Alzheimer's Disease Research Center
      • San Marcos, California, Stati Uniti, 92069
        • The Neuron Clinic
    • Colorado
      • Basalt, Colorado, Stati Uniti, 81621
        • Mountain Neurological Center
      • Englewood, Colorado, Stati Uniti, 80113
        • CenExel Rocky Mountain
    • Connecticut
      • Norwalk, Connecticut, Stati Uniti, 06851
        • Research Center for Clinical Trials
    • Florida
      • Aventura, Florida, Stati Uniti, 33180
        • Visionary Investigators Network
      • Boca Raton, Florida, Stati Uniti, 33487
        • SFM Clinical Research
      • Clermont, Florida, Stati Uniti, 34711
        • K2 Medical Research
      • Daytona Beach, Florida, Stati Uniti, 32114
        • K2 Medical Research Daytona
      • Fort Myers, Florida, Stati Uniti, 33912
        • Neuropsychiatric Research Center
      • Hallandale, Florida, Stati Uniti, 33009
        • Velocity Clinical
      • Jacksonville, Florida, Stati Uniti, 32216
        • Jacksonville Center for Clinical Research
      • Lady Lake, Florida, Stati Uniti, 32159
        • K2 Medical Research
      • Lake Worth, Florida, Stati Uniti, 33462
        • Headlands Research JEM
      • Lakeland, Florida, Stati Uniti, 33803
        • Accel Research Sites Lakeland (Alcanza)
      • Maitland, Florida, Stati Uniti, 32751
        • K2 Medical Research
      • Melbourne, Florida, Stati Uniti, 32940
        • ClinCloud Clinical Research
      • Merritt Island, Florida, Stati Uniti, 32952
        • Flourish Research/Merritt Island Medical Research
      • Miami, Florida, Stati Uniti, 33137
        • Miami Jewish Health
      • Naples, Florida, Stati Uniti, 34102
        • Aqualane Clinical Research
      • New Port Richey, Florida, Stati Uniti, 34652
        • Suncoast Clinical Research
      • Orlando, Florida, Stati Uniti, 32832
        • Conquest Research
      • Tampa, Florida, Stati Uniti, 33609
        • Axiom Brain Health, LLC
      • Winter Park, Florida, Stati Uniti, 32789
        • Conquest Research
    • Georgia
      • Decatur, Georgia, Stati Uniti, 30030
        • Accel Neurosciences
      • Gainesville, Georgia, Stati Uniti, 30501
        • CARE (Center for Advanced Research & Education)
    • Hawaii
      • Honolulu, Hawaii, Stati Uniti, 96817
        • Hawaii Pacific Neuroscience
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Stati Uniti, 60611
        • Re:Cognition Chicago
      • Chicago, Illinois, Stati Uniti, 60618
        • Charter Research Chicago
      • Chicago, Illinois, Stati Uniti, 60640
        • Great Lakes Clinical Trials/Flourish Research
      • Springfield, Illinois, Stati Uniti, 62702
        • Southern Illinois University
    • Indiana
      • Indianaopolis, Indiana, Stati Uniti, 46256
        • JWM Research
    • Kansas
      • Wichita, Kansas, Stati Uniti, 37214
        • Ascension via Christi Research
    • Louisiana
      • Metairie, Louisiana, Stati Uniti, 70006
        • Tandem Intermediate
    • Maryland
      • Pikesville, Maryland, Stati Uniti, 21208
        • Headlands Research Pharmasite
    • Massachusetts
      • Foxborough, Massachusetts, Stati Uniti, 02035
        • Neurology Center of New England, PC
      • Plymouth, Massachusetts, Stati Uniti, 02360
        • Headlands Research Easter Massachusetts
      • Russells Mills, Massachusetts, Stati Uniti, 02747
        • Mayflower Clinical
      • Springfield, Massachusetts, Stati Uniti, 01103
        • Elixia MA
    • Michigan
      • Farmington Hills, Michigan, Stati Uniti, 48334
        • Quest Research Institute
    • Mississippi
      • Flowood, Mississippi, Stati Uniti, 39232
        • Precise Research Center
    • Missouri
      • Chesterfield, Missouri, Stati Uniti, 63005
        • Clinical Research Professionals - Headlands Research
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89121
        • Oasis Clinical Trials LLC
    • New Jersey
      • Toms River, New Jersey, Stati Uniti, 08755
        • Cenexel Advanced Medical Research of New Jersey (AMRI)
      • West Long Branch, New Jersey, Stati Uniti, 07764
        • Advanced Clinical Institute
    • New York
      • Amherst, New York, Stati Uniti, 14226
        • Dent Neurologic Institute
      • Brooklyn, New York, Stati Uniti, 11235
        • SPRI
      • Lake Success, New York, Stati Uniti, 11042
        • Neurological Associates of Long Island
      • New York, New York, Stati Uniti, 10003
        • New York Neurology Associates
      • Staten Island, New York, Stati Uniti, 10314
        • Richmond Behavioral Associates
      • Syracuse, New York, Stati Uniti, 13210
        • Ichor Research
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27705
        • Duke University
      • Matthews, North Carolina, Stati Uniti, 28105
        • AMC Research/Flourish Research
    • Ohio
      • Beavercreek, Ohio, Stati Uniti, 45432
        • American Clinical Research Center
      • Centerville, Ohio, Stati Uniti, 45459
        • Valley Medical Research
      • Independence, Ohio, Stati Uniti, 44131
        • Insight Clinical Trials
    • Oregon
      • Portland, Oregon, Stati Uniti, 97210
        • Summit Headlands
    • Pennsylvania
      • Media, Pennsylvania, Stati Uniti, 19063
        • Suburban Research Associates
      • Plymouth Meeting, Pennsylvania, Stati Uniti, 19462
        • K2 Keystone
    • Rhode Island
      • East Providence, Rhode Island, Stati Uniti, 02914
        • Rhode Island Mood and Memory Research Institute
    • South Carolina
      • Summerville, South Carolina, Stati Uniti, 29486
        • Palmetto Primary Care & Specialty Physicians
    • Tennessee
      • Cordova, Tennessee, Stati Uniti, 38018
        • Neurology Clinic, P.C.
      • Nashville, Tennessee, Stati Uniti, 37204
        • K2 Medical Research Nashville
    • Texas
      • Austin, Texas, Stati Uniti, 78757
        • Senior Adults Specialty Research
      • Houston, Texas, Stati Uniti, 77094
        • NeuroMind Clinical Trials
      • Round Rock, Texas, Stati Uniti, 78681
        • Central Texas Neurology Associates
      • Wichita Falls, Texas, Stati Uniti, 76309
        • Grayline Research Center
    • Vermont
      • Bennington, Vermont, Stati Uniti, 05201
        • Memory Clinic, Inc.
    • Virginia
      • Arlington, Virginia, Stati Uniti, 22205
        • Sana Research
      • Fairfax, Virginia, Stati Uniti, 22031
        • Re:Cognition Fairfax

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 55 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

  2. Male or female, aged 55 - 85 years.

  3. MMSE 20-28 at screening and baseline.

  4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

  5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

  6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

  7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

  8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    • Intrauterine device (IUD),

    • Intrauterine hormone-releasing system (IUS),

    • Bilateral tubal occlusion,

    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    • IUD,
    • IUS,
    • Bilateral tubal occlusion.
  10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.

  11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

  12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.
  13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

  1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

  3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

  5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

  6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

  7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

  8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

  9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

  10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

  13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  14. Participants with learning disability or developmental delay.

  15. Participants whom the PI deems to be otherwise ineligible.

  16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  17. Participant is currently pregnant, breast-feeding, and/or lactating.

  18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

  19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Placebo capsule by mouth once daily for 18 months

Sperimentale: buntanetap

30mg capsule by mouth once daily for 18 months

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Lasso di tempo: From screening to 6-month readout, to end of treatment at 18 months.

ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.

From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Lasso di tempo: From screening to 6-month readout, to end of treatment at 18 months.

The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

From screening to 6-month readout, to end of treatment at 18 months.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 febbraio 2025

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

26 novembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

26 novembre 2024

Primo Inserito (Effettivo)

29 novembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi